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To the Editor,
I read the letter: ‘‘N-butyl cyanoacrylate glue: the best
hemostatic embolic agent for patients with acute arterial
bleeding.’’ First of all, I am grateful for their remarks and I
have two comments to make.
Firstly, the authors recommended skipping conservative
management in case of arterial extravasation on CT scan.
They prefer treating these patients with primary transarte-
rial embolization. I definitely agree with this recommen-
dation. My experience suggests that clinicians should be
encouraged to refer the patients with a suspicion of active
bleeding to the interventionalist as soon as possible,
preferably during acquisition of the CT scan. Thus, inter-
ventionalist can evaluate the CT scan, consult with the
clinician and transfer the patient to the angiography suite to
gain time. Otherwise, precious time is lost waiting for the
diagnosis of active bleeding and several consultations to be
done. Furthermore, when the interventionalist is unin-
formed about the patient, clinicians might prefer conser-
vative management primarily and refer the patient after a
large hematoma develops.
Secondly, I have an objection to the authors’ proposal
that only the use of authorized glues should be the rule and
Onyx should be used instead of Histoacryl. I believe this
is arguable in lack of availability of Trufill or Glubran2.
After adjusting the polymerization time with oily radio-
paque in 1982, Histoacryl has been increasingly used in
daily practice and in various embolization procedures [1].
Thus, I do not accept authors’ remarks about off-label use.
As in the case of Histoacryl, agent not released for a
special purpose can be used if this is common sense sup-
ported by the literature, at least in many countries [2]. On
the other hand, almost all literature on Onyx focuses on
neurologic interventions and aortic endoleak treatment.
There is no randomized controlled trial for treatment of
non-neurological bleeding, and case series are few. These
few studies mainly concern gastrointestinal and pulmonary
bleeding and reported Onyx use for spontaneous hema-
tomas is limited to 20 cases [3]. Furthermore, preparation
time of 15–20 min of Onyx–dimethylsulfoxide mixture,
requirement of slow injection and vasospasm in case of fast
injection limit its use in life-threatening hemorrhage. High
costs of Onyx and injection catheters are the other lim-
iting factors. Although Onyx seems effective, I still
suggest embolization with Histoacryl in lack of autho-
rized glues.
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